Geode Capital Management, LLC Arrowhead Pharmaceuticals, Inc. Transaction History

Geode Capital Management, LLC

$1.07 Trillion
Q1 2024

A detailed history of Geode Capital Management, LLC transactions in Arrowhead Pharmaceuticals, Inc. stock. As of the latest transaction made, Geode Capital Management, LLC holds 2,754,634 shares of ARWR stock, worth $69.5 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

2,754,634

Previous 2,326,876 18.38%

Holding current value

$69.5 Million

Previous $71.2 Million 10.65%

% of portfolio

0.01%

Previous 0.01%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	BUY	$27.21 - $39.48 $11.6 Million - $16.9 Million	427,758 Added 18.38%	2,754,634 $78.8 Million
Q4 2023 Feb 13, 2024	BUY	$21.2 - $31.03 $2.3 Million - $3.37 Million	108,623 Added 4.9%	2,326,876 $71.2 Million
Q3 2023 Nov 13, 2023	BUY	$26.2 - $36.08 $1.71 Million - $2.35 Million	65,203 Added 3.03%	2,218,253 $59.6 Million
Q2 2023 Aug 11, 2023	BUY	$25.16 - $41.38 $1.87 Million - $3.08 Million	74,523 Added 3.59%	2,153,050 $76.8 Million
Q1 2023 May 15, 2023	BUY	$23.68 - $38.51 $2.49 Million - $4.04 Million	104,976 Added 5.32%	2,078,527 $52.8 Million

Q4 2022 Feb 13, 2023	BUY	$28.0 - $40.56 $2.41 Million - $3.49 Million	86,154 Added 4.56%	1,973,551 $80 Million
Q3 2022 Nov 14, 2022	BUY	$29.63 - $48.31 $1.07 Million - $1.74 Million	36,020 Added 1.95%	1,887,397 $62.4 Million
Q2 2022 Aug 12, 2022	SELL	$27.79 - $50.61 $98,765 - $179,867	-3,554 Reduced 0.19%	1,851,377 $65.2 Million
Q1 2022 May 13, 2022	BUY	$39.62 - $69.97 $1.55 Million - $2.73 Million	39,031 Added 2.15%	1,854,931 $85.3 Million
Q4 2021 Feb 11, 2022	BUY	$58.09 - $82.51 $1.48 Million - $2.11 Million	25,523 Added 1.43%	1,815,900 $120 Million
Q3 2021 Nov 12, 2021	SELL	$58.38 - $84.96 $1.08 Million - $1.57 Million	-18,425 Reduced 1.02%	1,790,377 $112 Million
Q2 2021 Aug 13, 2021	BUY	$62.15 - $90.32 $3.25 Million - $4.72 Million	52,292 Added 2.98%	1,808,802 $150 Million
Q1 2021 May 12, 2021	BUY	$61.35 - $90.47 $9.09 Million - $13.4 Million	148,237 Added 9.22%	1,756,510 $116 Million
Q4 2020 Feb 12, 2021	BUY	$43.82 - $85.37 $3.51 Million - $6.83 Million	80,045 Added 5.24%	1,608,273 $123 Million
Q3 2020 Nov 13, 2020	SELL	$33.21 - $51.27 $871,031 - $1.34 Million	-26,228 Reduced 1.69%	1,528,228 $65.8 Million
Q2 2020 Aug 13, 2020	BUY	$26.12 - $43.27 $1.01 Million - $1.68 Million	38,813 Added 2.56%	1,554,456 $67.2 Million
Q1 2020 May 14, 2020	BUY	$20.56 - $63.12 $1.71 Million - $5.26 Million	83,282 Added 5.81%	1,515,643 $43.6 Million
Q4 2019 Feb 13, 2020	BUY	$28.14 - $73.01 $3.25 Million - $8.44 Million	115,576 Added 8.78%	1,432,361 $90.9 Million
Q3 2019 Nov 12, 2019	BUY	$26.26 - $34.86 $892,813 - $1.19 Million	33,999 Added 2.65%	1,316,785 $37.1 Million
Q2 2019 Aug 14, 2019	BUY	$17.43 - $28.82 $2.09 Million - $3.46 Million	120,083 Added 10.33%	1,282,786 $34 Million
Q1 2019 May 14, 2019	BUY	$12.05 - $20.18 $2 Million - $3.35 Million	166,245 Added 16.68%	1,162,703 $21.3 Million
Q4 2018 Feb 13, 2019	BUY	$10.74 - $19.7 $797,928 - $1.46 Million	74,295 Added 8.06%	996,458 $12.4 Million
Q3 2018 Nov 13, 2018	BUY	$14.0 - $20.3 $675,514 - $979,495	48,251 Added 5.52%	922,163 $17.7 Million
Q2 2018 Aug 14, 2018	BUY	$6.37 - $14.02 $1.55 Million - $3.41 Million	243,281 Added 38.58%	873,912 $11.9 Million
Q1 2018 May 15, 2018	BUY	$3.72 - $7.64 $105,220 - $216,097	28,285 Added 4.7%	630,631 $4.55 Million
Q4 2017 Feb 13, 2018	SELL	$3.14 - $4.5 $54,585 - $78,228	-17,384 Reduced 2.81%	602,346 $2.22 Million
Q3 2017 Nov 14, 2017	BUY	$1.69 - $4.33 $101,405 - $259,812	60,003 Added 10.72%	619,730 $2.68 Million
Q2 2017 Aug 14, 2017	BUY	N/A	559,727	559,727 $906,000

Others Institutions Holding ARWR

# of Institutions

296

Shares Held

88.5M

Call Options Held

905K

Put Options Held

387K

View Full List

About ARROWHEAD PHARMACEUTICALS, INC.

Ticker ARWR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 105,849,000
Market Cap $2.67B
Description
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...

More about ARWR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.

Account

Geode Capital Management, LLC Arrowhead Pharmaceuticals, Inc. Transaction History